#directed evolution

[hybridmindthoughtsreloaded]

George Webb's reporting on Jordon Walker at Boston Consulting Group gets undeniable validation from an expert. Validation always takes a while, but you can’t argue with BCG purchase orders and work orders. Jordon Walker was a Contractor at Pfizer doing “communications”, not science. https://twitter.com/RealGeorgeWebb1/status/1629077451732131841?s=20

[gettothedancing]

Pfizer Executive: ‘Mutate’ COVID via ‘Directed Evolution’ for Company to Continue Profiting Off of Vaccines … ‘COVID is Going to be a Cash Cow for Us’ … ‘That is Not What We Say to the Public’ … ‘People Won’t Like That’ … ‘Don’t Tell Anyone’

Investigating and exposing corruption in both public and private institutions.

[hybridmindthoughtsreloaded]

Project Veritas Jordon Walker Papers Lead Directly To Klaus Schwab's World Economic Forum

Jordon Walker's Boston Consulting Group Paper Leads Directly To WEF-BCG Partnership

Despite giving Project Veritas CEO James O’Keefe a detailed explanation of how Gain of Function was not equivalent to Direct Evolution, Project Veritas continues to conflate the two and promotes the Mass Formation Psychosis around only Jordan Walker and Pfizer, ignoring the must more Senior co-authors of the BCG Remdesivir paper. Meanwhile, world-renowned cardiologist, Peter McCullough, a leading expert on COVID, calls me “very credible” with my linkage of Boston Consulting Group to Remdesivir.

In addition to providing the distinction between Gain of Function and Directed Evolution on a live Twitter Space with 5,000 witnesses, I also outlined the key players with the real status and gravitas at Boston Consulting Group who engineered the rigging of Remdesivir in American hospitals as the only Standard of Care.

I am now wondering if Project Veritas is working on a “Boston Consulting Massacre” of its own, leaving out the key players at Boston Consulting leading to the World Economic Forum and Klaus Schwab himself. We will continue to follow this story as new information develops.

[gorobagaikwad]

Technological Trends and the Digital Future of the Enzymes Market

The Enzymes Market is currently at the intersection of biology and information technology, a convergence that is accelerating the industry toward its 2030 goal of USD 28.17 billion. In 2023, the market was worth USD 13.74 billion, but the introduction of artificial intelligence and machine learning into enzyme discovery has fundamentally changed the speed of innovation. Previously, discovering a new enzyme for an industrial process could take years of manual screening. Today, AI algorithms can predict the structure and function of millions of protein sequences in a matter of days, allowing researchers to skip the "hit-or-miss" phase and move directly to the most promising candidates.

The concept of "Enzymes 4.0" is becoming a reality in 2026. This refers to the use of digital twins and real-time monitoring in enzymatic fermentation. By creating a digital replica of a fermentation tank, manufacturers can optimize the nutrient levels, temperature, and agitation in real-time to maximize enzyme yield and purity. This level of process control reduces waste and lowers the cost of production, making high-end enzymes more affordable for a wider range of industries. The 10.5% CAGR is as much a result of these manufacturing efficiencies as it is of new product discoveries, ensuring a healthy profit margin for leading producers.

Directed evolution, a technique that won the Nobel Prize in Chemistry, has also become a standard industrial tool. By mimicking natural selection in the laboratory, scientists can "evolve" enzymes to perform better in non-natural environments, such as high-temperature chemical reactors or organic solvents. This has opened up the use of enzymes in pharmaceutical synthesis, where they can replace precious metal catalysts that are often expensive and toxic. In 2026, enzymatic synthesis is becoming the preferred method for producing complex drug molecules, leading to cleaner pharmaceuticals with fewer impurities. This technological maturation is a key driver for the market's high projected valuation.

A significant shift in genomic research tools is also supporting the rise of "cell-free" enzyme production. Instead of growing whole microbes to produce enzymes, researchers are using just the necessary cellular machinery to synthesize proteins in a test tube. This approach is much faster and allows for the production of enzymes that might be toxic to a living host cell. By 2030, cell-free systems are expected to be a major manufacturing platform for high-value therapeutic and diagnostic enzymes, providing a level of speed and flexibility that traditional fermentation cannot match.

As we look to the end of the decade, the global enzymes market will be a highly digitized, precision-driven ecosystem. The ability to "print" DNA and express custom enzymes on demand will decentralize the industry, allowing local facilities to produce the specific catalysts they need for local challenges. Whether it is a clinic in a remote area producing diagnostic enzymes or a factory producing bioremediation enzymes to clean up a local spill, the future is decentralized and highly responsive. With a market size projected to surpass USD 28 billion, the enzymes sector is not just growing; it is evolving into a foundational technology for a sustainable and healthy 21st century.

[geopolicraticus]

Friday 30 May 2025

Grand Strategy Newsletter

The View from Oregon – 343

The Embodiment Imperative for Post-Biological Intelligence

…in which I discuss optimal embodiment, reflexive and irreflexive constraints on intelligence, post-biological emergent discontinuity, directed evolution, and compromises with optimality…

Substack: https://geopolicraticus.substack.com/p/the-embodiment-imperative-for-post

Medium: https://jnnielsen.medium.com/the-embodiment-imperative-for-post-biological-intelligence-88e28ca66311

Reddit: https://www.reddit.com/r/The_View_from_Oregon/comments/1l54pz6/the_embodiment_imperative_for_postbiological/

[hybridmindthoughtsreloaded]

Finding the true use of #DirectedEvolution at Pfizer. Not Jordon Walker. Maxygen and Frances Arnold is your answer as we said. Codexis acquired the rights to sell on to Pfizer.

https://twitter.com/RealGeorgeWebb1/status/1629251551016505346?s=20

[ultramaga]

If you want to stop the plagues, stop Pfizer. They should be arrested, tried, and executed, for crimes against humanity.

[woodrowwood]

Directed Evolution. Learn something new everyday. Kill some people, get money for the vaccine.

https://www.instagram.com/reel/Cn3E0B0g2BK/?utm_source=ig_web_copy_link